University of Melbourne
This is a trial of tirzepatide in people with obesity and knee osteoarthritis. The main purpose of this study is to see if tirzepatide can reduce number of these participants who require a knee replacement. Participants will be randomized to take a weekly injection of tirzepatide or a placebo for a total of 72 weeks.
Obesity
Knee Osteoarthritis
Osteoarthritis, Knee
Tirzepatide
Placebo
PHASE4
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 352 participants |
Masking : | QUADRUPLE |
Primary Purpose : | TREATMENT |
Official Title : | Effect of Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA): A Randomized, Double-Blind, Placebo-Controlled Trial |
Actual Study Start Date : | 2024-11-19 |
Estimated Primary Completion Date : | 2027-05 |
Estimated Study Completion Date : | 2037-05 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
St Vincents Hospital Melbourne
Fitzra, Victoria, Australia, 3065
RECRUITING
Western Health
Melbourne, Victoria, Australia, 3011
RECRUITING
Austin Health-Repatriation Hospital
Melbourne, Victoria, Australia, 3084
RECRUITING
Eastern Health
Melbourne, Victoria, Australia, 3128